Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (7.407%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

1 Aug 2005 07:01

Angle PLC01 August 2005 For Immediate Release 1 August 2005 ANGLE plc ("ANGLE" or the "Company") Formation of Executive Management Board and Board Change ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryannounces the formation of an Executive Management Board which will reportdirectly to the ANGLE plc Board. In recognition of the Company's recent successes, rapid expansion and futureprospects across the United Kingdom, United States and the Middle East, ANGLEhas strengthened its management structure and promoted Stephen Bates, currentlyDirector of UK Ventures, to UK Chief Executive. Responsibility for HR,marketing, IT and operations will now be devolved from the Board to regionalchief executives ensuring full responsibility for all activities in theirrespective regions. With immediate effect, the Executive Management Board will consist of Group CEO,Andrew Newland and Finance Director, Ian Griffiths, together with: Stephen Bates, UK Chief Executive Stephen Bates has an MA in engineering, and an MBA. Following 10 years withinthe product development industry his career has taken him to ScientificGenerics, Arthur D. Little and Marks & Spencer prior to joining ANGLE in 2004.Dr Gary Evans, US Chief Executive Gary Evans has a BSc in Chemistry, a PhD in Physical Chemistry, and a Diploma inManagement Science and was Visiting Professor in Innovation Management at theRobert Gordon University, Aberdeen. Following a career with Cambridge LifeSciences and then Scottish Enterprise, Dr. Evans joined ANGLE in 1997. Dr Eulian Roberts, Middle East Chief Executive Eulian Roberts has a BSc in Microbiology, a PhD in Molecular Biology and an MBA.He gained three years' post-doctoral experience and then joined ScottishEnterprise. He then became chief executive of the Stirling University InnovationPark, managing director of Coventry University Enterprises Limited and adirector of the UK Science Park Association. Dr Roberts joined ANGLE in 1998. As a result of these changes, Dawson Buck will be stepping down from hisposition as Deputy Chief Executive, with immediate effect. He remains a directorof ANGLE's venture companies, Corpora plc and Provexis plc. Commenting on the new organisational structure, Group CEO, Andrew Newland, said: "The formation of an Executive Management Board establishes a clear managementstructure and accountability by region which will improve the efficiency andintegration of our Consulting & Management and Ventures operations, streamlineoverheads and facilitate our continuing rapid growth. The new management structure gives us the platform we need to grow the businesssubstantially. I am delighted to have such high calibre individuals within theExecutive Management Board. I would also like to put on record my thanks to Dawson Buck for all hiscontributions to the ANGLE Board over the last five years." For further information ANGLE plcAndrew Newland, Chief Executive Tel: +44 (0)1483 295830 Buchanan Communications Tel: +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update
3rd Jun 20157:00 amRNSAppointment of Scientific Adviser
26th May 20157:01 amRNSNew Patent Grants
21st Apr 20157:00 amRNSOvarian Cancer Update
20th Apr 20157:00 amRNSSidney Kimmel Cancer Centre
14th Apr 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSOffer to Shareholders
25th Feb 20151:11 pmRNSIssue of Equity
20th Feb 20154:05 pmRNSHolding(s) in Company
16th Feb 20157:01 amRNSMD Anderson Collaboration
16th Feb 20157:00 amRNSPlacing, Subscription and Offer
29th Jan 20157:00 amRNSInterim Results
27th Jan 20157:01 amRNS"Unprecedented Specificity" in Ovarian Cancer
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
21st Jan 20153:00 pmRNSFurther information re Director's share transfer
19th Jan 20157:00 amRNSNotification of Interim Results
8th Jan 20157:00 amRNSCorporate Collaboration
15th Dec 20147:00 amRNSCancer Research Manchester Institute Publication
12th Nov 20147:00 amRNSFurther information re Director's share transfer
10th Nov 20147:00 amRNSIssue of Share Options
31st Oct 20147:00 amRNSADR PROGRAMME
21st Oct 20147:00 amRNSDirector's Share Transfer
17th Oct 20147:00 amRNSCollaboration with Barts Cancer Institute
17th Oct 20147:00 amRNSKey Opinion Leaders Report on Parsortix System
30th Sep 20144:30 pmRNSResult of AGM
30th Sep 20147:00 amRNSCollaboration with Thomas Jefferson University
25th Sep 20147:00 amRNSADR Programme, FDA Update and US Appointment
19th Sep 20147:00 amRNSBreast Cancer Collaboration
17th Sep 20147:00 amRNSCollaboration with Medical University of Vienna
8th Sep 20147:00 amRNSHamburg-Eppendorf Collaboration
4th Aug 20147:00 amRNSParsortix Granted Second US Patent
23rd Jul 20147:00 amRNSPreliminary Results
22nd Jul 20147:00 amRNSParsortix Evaluation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.